Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2Valneva will host a live webcast on this announcement at 3 p.m.

Valneva获得了LimmaTech S4V志贺氏疫苗候选疫苗的全球独家许可证，并为Valneva的研发管道LimmaTech增加了一项有吸引力的2期临床资产，以获得预付款，有资格获得未来的里程碑和版税付款，并将通过2期合作进行S4V临床开发Valneva将于下午3点就此公告举行在线直播。

CEST/9 a.m. EDT today. Please refer to this link: https://edge.media-server.com/mmc/p/ck932u2n Saint-Herblain (France) and Schlieren (Zurich), August 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced that the companies have entered into a strategic partnership and exclusive licensing agreement for the development, manufacturing and commercialization of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis.

CEST/美国东部时间今天上午9点。请参考此链接：https://edge.media-server.com/mmc/p/ck932u2n圣赫伯兰（法国）和纹影（苏黎世），2024年8月1日–Valneva SE（纳斯达克：VALN；巴黎泛欧交易所：VLA），一家专业疫苗公司和LimmaTech Biologics AG，一家临床阶段的生物技术公司，开发用于预防危及生命的疾病的疫苗，今天宣布，这些公司已经就志贺氏菌4V（S4V）的开发，制造和商业化达成了战略合作伙伴关系和独家许可协议，志贺氏菌4V是一种针对志贺氏菌病的四价生物结合疫苗候选物。

Shigellosis, caused by Shigella bacteria, is the second leading cause of fatal diarrheal disease worldwide. It is estimated that up to 165 million cases of disease and an estimated 600,000 deaths are attributed to Shigella each year1, particularly among children in Low- and Middle-Income Countries (LMICs).

由志贺菌引起的志贺菌病是全球致命性腹泻病的第二大原因。据估计，每年有多达1.65亿例疾病病例和估计有60万人死于志贺菌1，特别是在中低收入国家（LMIC）的儿童中。

No approved Shigella vaccine is currently available and the development of Shigella vaccines has been identified as a priority by the World Health Organization (WHO)2. Shigellosis also affects international travelers from high-income countries and deployed military personnel in endemic regions. The global market for a vaccine against Shigella is estimated to exceed $500 million annually3.

目前尚无经批准的志贺菌疫苗，世界卫生组织（WHO）2已将志贺菌疫苗的开发确定为优先事项。志贺菌病还影响来自高收入国家的国际旅行者和在流行地区部署的军事人员。据估计，全球痢疾疫苗市场每年将超过5亿美元3。

Under the terms of the agreement with Valneva, LimmaTech will receive an upfront payment of €10.

根据与Valneva的协议条款，LimmaTech将收到10欧元的预付款。

Attachment

附件

2024_08_01_VLA_LMTB_S4V_PR_EN_Final

2024年8月01日VLA_LMTB_S4V_PR_EN决赛